Table 1.
Study | Subjects/animals | Intervention | Tissue examined | Main findings |
---|---|---|---|---|
Irisin | ||||
Bostrom et al., 1995 | Muscle creatine kinase promoter (MCK)‐PGC1‐α transgenic and wild type BALB/c mice | 3 weeks of swimming | – | Increase of brown‐like genes on the WAT |
Epididymal fat | Twofold increase in Ucp1 mRNA | |||
Subcutaneous inguinal | 65‐fold increase in Ucp1 mRNA | |||
3 weeks of wheel running | Visceral, epididymal | Twofold increase in Ucp1 mRNA | ||
Subcutaneous inguinal | 25‐fold increase in Ucp1 mRNA | |||
Brown adipose tissue | Increase whole‐body energy expenditure | |||
Non‐diabetic men | 10 weeks of endurance training at ~65% of VO2max | Muscle biopsies | FNDC5, VEGFB and TIMP4, LRG1 and mRNAs | |
Blood | Circulating Irisin | |||
BALB/c mice, primary adipocytes | Incubation with FNDC5 | Cell culture | 7 to 500‐fold increase of Ucp1; threefold in PPARγ mRNA | |
Kim et al., 2013 | Lean and overweight/obese adults | 8 weeks of resistance training at 65–80% of 1RM | Blood | ~17.5% irisin plasma levels |
8 weeks of endurance training at 65–80% of HRmax | body fat and BMI | |||
Huh et al., 2005 | Young males(± 20 years) | 8 weeks or 30 min of endurance training | Blood | ~18% circulating irisin |
Metrnl | ||||
Rao et al., 2010 | Young men | RT at 80% 1RM + 30 min of cycling at 70% VO2peak | Vastus lateralis muscle biopsies | metrnl up to 4 h post exercise. mRNA peak expression was at 1 h |
Wild‐type C57/BL6J, BALB/cJ Myo‐PGC‐1α4, ΔdbGATA mice, metrnl KO mice | Subcutaneous fat; epididymal fat; | M2‐macrophages gene markers; inflammation genes in the AT (TNF‐α, IFN‐γ and IL‐1β) | ||
60 min of downhill running exercise at 15 m·min−1 | Thermogenesis; mitochondrial gene programme; UCP‐1 (~3.5), DIO2, PGC‐1α, ERR‐α mRNA | |||
Brown adipose tissue | metrnl mRNA and thermogenic gene programme; UCP‐1 mRNA in BAT | |||
Quadriceps and triceps muscle | ~fourfold increase of metrnl mRNA | |||
Blood | ~twofold increase in circulating metrnl | |||
Adenovirus injection to deliver full‐length metrnl to the liver | Liver and blood | ~20‐fold increase in liver mRNA and ~five to sixfold in plasma | ||
Culture of myotubes PGC‐1α4 expression | ~eightfold increase of metrnl mRNA | |||
Fibroblast growth factor 21 | ||||
Cuevas‐Ramos et al., 2009 | Sedentary young women | 2 weeks of endurance exercise at 85% of HR | Blood | ~66% circulating levels of FGF‐21; ~25% triglycerides; Epinephrine; FFA (~50%) |
Tanimura et al., 2015 | Male ICR mice | 60 min of endurance exercise at 10–30 m·min−1 | Liver | mRNA and protein levels of FGF‐21 |
Blood | Serum FGF‐21 | |||
Gastrocnemius muscle | mRNA and protein of FGF‐21; p‐Akt/Akt protein | |||
Young sedentary men | Single bout for 60 min at 75% of VO2max | Blood | Serum FGF‐21, NEFA, 3‐hydroxybutyric acid | |
Kim et al., 2015 | Male C57/BL6 mice | 30 min of endurance exercise at 25 m·min−1 | Blood | FGF‐21 serum levels |
30 min of endurance exercise at 50 or 80% of VO2max | Liver | FGF‐21, PPARα, ATF4 mRNA | ||
Male adults | Blood | FGF‐21 serum levels only 1 h after end of bout | ||
Slusher et al., 2016 | Obese and lean adults | 30 min of endurance training at 75% of VO2max | Blood | FGF‐21 in lean subjects regardles the time and in the obese only after 1 h post bout |
Increased circulatory FGF‐21 correlates to total relative energy expenditure | ||||
Hansen et al., 2016 | Young lean and type 2 diabetic men | 2 h of endurance exercise at 60% of VO2max + Patients that underwent through pancreatic clamp | Blood | Glucagon/Insulin ratio; Plasma FGF‐21 in controls; |
In type 2 diabetic patients and Pancreatic clamp FGF‐21 is abolished in plasma | ||||
IL‐15 | ||||
Kim et al., 2015 | Male Zucker diabetic fatty rats | 12 weeks – 60 min of endurance training at 15–20 m·min−1 | Soleus and gastrocnemius muscles | IL‐15 protein levels in S. muscle |
Bazgir et al., 2015e | Young male non‐ and athletes | Two bouts of RT, one focusing on CON at 70–80% 1RM and the second on ECC at 90–100% 1RM ‐with 8 to 10 repetitions | Blood | IL‐15 serum levels |
hs‐CRP levels in athletes | ||||
hs‐CRP and TNF‐α levels in non‐athletes | ||||
Quinn et al., 2015 | IL‐15‐KO and IL‐15Rα KO mice | Endurance training at 15‐17 m·min−1 until exhaustion | Gastrocnemius muscle | Endurance capacity in KO mice; MHC mRNA |
IL‐15 mRNA in G. muscle; Serum IL‐15 in KO mice | ||||
PPARδ and SIRT1 mRNA and protein after IL‐15 injection and 3 h post bout | ||||
Acute injection of IL‐15 | Blood | IL‐15Rα in Control and KO‐mice | ||
IL‐15 circulating levels in IL‐15Rα‐KO mice | ||||
PGC‐1α and 1β in SKM of IL‐15KO | ||||
IL15Rα after an acute bout of exercise | ||||
Pistilli et al., 2008 | IL‐15Rα KO mice | 14 h data from Voluntary wheel exercise | EDL, gastrocnemius and quadriceps muscle | Ambulatory activity, fatigue resistance and wheel revolutions |
IL‐15 mRNA in muscles of IL‐15Rα‐KO mice IL‐15, Ppard, Pgc‐1α, citrate synthase, SERCAII and calsequestrin mRNA in EDL and gastrocnemius of IL‐15Rα‐KO mice | ||||
IL‐6 | ||||
McGinnis et al., 2015 | C57/Bl6 or IL‐6−/− mice | 3 days of 60 min of treadmill exercise at 18 m·min−1 prior I/R surgery procedure | Serum | ~4.5‐fold in IL‐6 and sIL‐6R serum concentration after 30 min exercise in controls; IL‐6R in G. muscle and heart after exercise in C57/Bl6 mice |
Gastrocnemius muscle | COX‐2 mRNA and protein post exercise; iNOS and p‐STAT protein before and after exercise in IL‐6−/− in G. muscle | |||
of ~65% of necrotic area, ECG score protection against arrhythmias in C57/Bl6 | ||||
Heart | p‐p44/42 MAPK and p‐p38 MAPK proteins in the myocardium after the exercise in C57/Bl6 mice |